ערך בספרים למניה: Verona Pharma plc (VRNA)
The commercialization of the COPD inhalant by Verona Pharma plc (VRNA) is driving operating leverage growth and the recoupment of R&D costs. The drug Ohtuvayre creates a closed therapeutic loop for pulmonologists with no existing equivalents. The book value per share on the current GURU.Markets platform chart shows that the value of 3.26 expresses the metric level. The strategy is based on pairing innovative molecules with proprietary nebulizers for precise drug delivery.
veronapharma.com - פילוחים אנליטיים ומדדי מפתח (VRNA)
Book value per share determines the actual value of net assets available to the holder of each security. The trend in the calculated book value per share reveals the gap between market quotes and the asset base. This metric is calculated by dividing equity minus liabilities by the number of shares. Growth in this metric confirms the business capitalization. For Verona Pharma plc (VRNA), this is supported by the commercial success of Ensifentrine and the protection of margins via patents.